The Rise of GIP: From Biology to Medicine

In this episode, we explore the fascinating history, fall, and resurgence of GIP (glucose-dependent insulinotropic polypeptide) in diabetes therapy. Once overshadowed by GLP-1, GIP is now back in the spotlight, thanks to dual and triple agonist therapies like tirzepatide. Experts discuss how GIP signaling in the brain may influence appetite and weight regulation, why early studies underestimated its therapeutic value, and what the future holds for multi-agonist drug development in metabolic disease. Join Prof. Michael Nauck from the University of Bochum, Dr. Alice Adriaenssens from UCL and our host, Vivienne Perry as they revisit the incretin story, unpack recent breakthroughs in GIP biology, and offer a glimpse into the next wave of gut hormone-based therapies that go beyond glucose control to address obesity and energy expenditure.

There are no comments yet.

Please log in to write the first comment.